# Test Results: statistics/design-review.md

> ⚠️  Raw model output captured automatically by the cross-model test harness on 2026-06-25.
> This output is **not yet verified**. An author must read the output and set the
> assessment below before this counts as a tested result (see CLAUDE.md, Hard Rules).

## Test Metadata
- **Prompt:** statistics/design-review.md
- **Model:** nemotron-3-super-120b
- **Model ID (pinned):** Nemotron-3-Super-120B-A12B-NVFP4
- **Endpoint:** https://copilot-dev.cqls.oregonstate.edu/llm/nemotron3-super-120b-nvfp4/v1
- **Date:** 2026-06-25
- **Tester:** cross-model-harness
- **Assembly strategy:** test-only
- **Temperature:** 0.0

## Test Input Used
Standard test input from prompt file (`## Test Input`).

## Filled Prompt
````
Context: I am planning an experiment to test whether a high-fiber diet alters gut microbiome-immune interactions in a mouse model of autoimmune disease. I want critical feedback before I begin.

Research question: Does dietary fiber supplementation modify gut microbiome composition and reduce autoimmune inflammation in the EAE mouse model?

Experimental design:
- Study system: C57BL/6 mice, 8 weeks old, female, EAE model (MOG-induced)
- Treatment groups:
  1. EAE + standard diet (n=12)
  2. EAE + high-fiber diet (n=12)
  3. No EAE + standard diet (n=6)
  4. No EAE + high-fiber diet (n=6)
- Sample size: Based on previous EAE studies in our lab showing adequate power at n=10
- Controls: Groups 3-4 are healthy controls
- Randomization: Mice assigned to groups at weaning
- Blinding: Clinical scoring will be performed by blinded observer
- Outcome measures: Clinical EAE score (daily), microbiome composition (16S), T cell populations (flow cytometry)
- Timepoints: Fecal samples at days 0, 7, 14, 21; immune analysis at day 21

Potential confounders I've considered:
- Cage effects (2 cages per group)
- Litter effects
- Food consumption differences

Planned analysis: Compare clinical scores with repeated measures ANOVA; compare microbiome with PERMANOVA; correlate microbiome changes with immune parameters.

Task: Review this experimental design critically. Please identify:

1. **Strengths**: What aspects of the design are well-constructed?

2. **Missing controls**: Are there controls that should be added?

3. **Potential confounds**: What factors could produce the expected result without the hypothesized mechanism?

4. **Threats to validity**:
   - Internal validity: Could something other than the treatment explain results?
   - External validity: How generalizable are potential findings?

5. **Statistical concerns**:
   - Is the sample size likely adequate?
   - Does the design match the planned analysis?
   - Are there design features that complicate analysis?

6. **Practical issues**: What could go wrong during execution?

7. **Recommendations**: Prioritized list of suggested improvements

Constraints:
- Be critical—I want to find problems now, not after data collection
- Distinguish between essential fixes and nice-to-haves
- If you need more information to evaluate an aspect, ask
- Don't assume expertise I may not have; explain concerns clearly
````

## Model Output
````


Below is a point‑by‑point critical appraisal of your plan. I have tried to separate **essential fixes** (things that, if left unaddressed, could seriously undermine the interpretability of the results) from **nice‑to‑have improvements** (which would strengthen the study but are not strictly required for a valid test of the hypothesis). Where I need more information to judge adequacy, I note what I would ask for.

---

## 1. Strengths  

| Aspect | Why it’s good |
|--------|---------------|
| **Clear hypothesis & outcome hierarchy** – clinical score (phenotype) → microbiome → immune read‑outs. | Makes it easy to follow the causal chain you want to test. |
| **Inclusion of healthy controls (no EAE) for both diets** – lets you see whether the fiber itself shifts baseline immunity or microbiota. | Essential for disentangling disease‑specific vs. diet‑only effects. |
| **Blinded clinical scoring** – reduces observer bias. | Good practice for a subjective endpoint. |
| **Randomisation at weaning** – spreads litter and early‑life effects across groups. | Helps control for litter‑related microbiome drift. |
| **Cage replication (2 cages/group)** – begins to address cage effects. | Acknowledges a known source of non‑independence. |
| **Multiple time‑points for faecal sampling** – enables longitudinal microbiome tracking. | Allows you to see whether changes precede or follow clinical onset. |
| **Planned use of PERMANOVA for community data** – appropriate for testing overall composition shifts. | Standard, well‑understood method. |
| **Flow cytometry for T‑cell subsets** – directly relevant to EAE pathogenesis. | Provides mechanistic read‑out. |

---

## 2. Missing Controls  

| Missing control | Why it’s essential (or highly recommended) | How to add it |
|-----------------|--------------------------------------------|---------------|
| **Pair‑fed control for the high‑fiber diet** | Fiber diets often differ in caloric density, palatability, and bulk, which can affect food intake, body weight, and gut transit time—all of which influence immunity and microbiota. Without matching intake, any observed effect could be due to reduced calories rather than fiber per se. | Provide a third diet that is iso‑caloric and iso‑bulky to the high‑fiber diet (e.g., standard diet + indigestible cellulose filler) and feed the same amount of food as the high‑fiber group, or monitor daily food intake and adjust portions to match intake across groups. |
| **Baseline (pre‑treatment) microbiome & immune phenotype** | You need to know whether groups start equivalent; randomisation at weaning does not guarantee identical starting microbiota, especially if litters are not split. | Collect faecal samples (and optionally a small blood draw) at day 0 (before diet starts) and use these as covariates or to confirm no pre‑existing differences. |
| **Sham‑diet control for the EAE induction** (optional but useful) | Some diet components (e.g., certain emulsifiers) can influence EAE severity independent of fiber. | Keep the “standard” diet identical across all EAE groups; if you change any ingredient to boost fiber, verify that the base diet is unchanged. |
| **Antibiotic‑ or germ‑free validation (mechanistic control)** | To claim that the effect is mediated via the microbiome, you should show that removing microbiota abolishes the fiber benefit. | In a separate pilot, treat a subset of mice with broad‑spectrum antibiotics or use germ‑free mice colonised with faecal transplants from high‑fiber vs. standard donors. |
| **Sex‑balanced cohort (if external validity is a goal)** | EAE is more severe in females, but immune‑microbiome interactions may differ in males. | Add a parallel male cohort (same n) or at least justify why females only are sufficient for your aims. |

---

## 3. Potential Confounds (factors that could mimic the hypothesized effect)

| Confounder | How it could produce a spurious “fiber improves EAE” result |
|------------|------------------------------------------------------------|
| **Differential food intake / energy balance** | High‑fiber diets are often less palatable or more bulky → mice eat less → lower body weight → reduced inflammation independent of fiber. |
| **Coprophagy & cage‑to‑cage microbiota transfer** | Mice in the same cage share microbes; if one cage happens to have a milder EAE phenotype, the effect could be attributed to diet when it’s actually cage‑specific microbiota. |
| **Litter effects** | If litters are not split across diet groups, early‑life microbiota (strongly litter‑driven) could confound later differences. |
| **Variability in MOG‑35‑55 emulsion quality** | Incomplete emulsification can lead to variable disease onset; if, by chance, the high‑fiber group receives a slightly less potent inoculum, scores will be lower. |
| **Stress from handling or diet change** | Switching diets at weaning can cause a brief stress period that alters immunity; if the timing differs between groups, it could masquerade as a diet effect. |
| **Seasonal or vendor‑driven microbiota drift** | If the experiment runs over several weeks, baseline microbiota may shift, interacting with diet. |
| **Sex‑specific hormone fluctuations** | Estrous cycle can influence EAE severity; if not tracked, variability could be mistaken for diet effect. |

---

## 4. Threats to Validity  

### Internal Validity  
* **Confounding by intake/weight** – see above.  
* **Cage‑level non‑independence** – mice sharing a cage are not independent replicates; treating each mouse as an independent unit inflates Type I error.  
* **Litter clustering** – if litters are not split, siblings share early environment and genetics, again violating independence.  
* **Unblinded diet preparation** – if the person preparing diets knows which group is getting fiber, subtle differences (e.g., pellet size, moisture) could arise.  
* **Timing of immune read‑out** – only sampling at day 21 (peak disease) may miss earlier mechanistic events; a transient immune shift could be overlooked, leading to a false‑negative microbiome‑immune correlation.  

### External Validity  
* **Sex restriction (female only)** – limits extrapolation to males or to human populations where both sexes are affected.  
* **Single genetic background (C57BL/6)** – other strains show different EAE susceptibility and microbiome‑immune interactions; results may not generalize.  
* **Diet composition** – if you use a commercial “high‑fiber” chow that differs in fat, protein, or micronutrients beyond fiber, the effect may not be attributable to fiber alone.  
* **Laboratory‑specific husbandry** – cage density, bedding type, water source, and facility microbiota can shape baseline immunity; findings may not replicate elsewhere.  

---

## 5. Statistical Concerns  

| Issue | Why it matters | Suggested remedy |
|-------|----------------|------------------|
| **Sample size justification** | You cite “previous EAE studies in our lab showing adequate power at n=10” but do not show the calculation (effect size, variance, alpha, power). EAE scores are often highly variable; a post‑hoc power check may reveal under‑powering. | Perform an a priori power analysis using pilot data or published variance for clinical score (e.g., mean difference = 1.0, SD ≈ 1.2, α=0.05, power=0.8 → n≈14/group). Adjust n accordingly. |
| **Repeated‑measures ANOVA assumptions** | Requires sphericity and normality of residuals; clinical scores are often ordinal and non‑normal, with missing data if mice die or are euthanized early. | Use a linear mixed‑effects model (LMM) with mouse as a random effect, day as a fixed effect, and diet*day interaction. This handles missing data, unequal intervals, and non‑sphericity. |
| **Treating each mouse as independent despite cage effects** | Ignoring cage clustering inflates degrees of freedom → false positives. | Include cage as a random effect in the LMM (or use a generalized estimating equations approach with an exchangeable correlation structure). |
| **PERMANOVA on 16S data** | PERMANOVA is sensitive to differences in dispersion (heterogeneity of variance) as well as location; a significant result could reflect varied spread rather than a true centroid shift. | Test for homogeneity of dispersions (PERMDISP) and report both. Consider complementary approaches (e.g., distance‑based redundancy analysis, DESeq2/ANCOM for differential abundance). |
| **Multiple testing** | You will likely test many taxa, immune subsets, and correlations. | Apply false‑discovery rate (FDR) correction (Benjamini‑Hochberg) for exploratory taxa; pre‑specify a limited set of hypotheses for confirmatory tests (e.g., primary outcome = clinical score, secondary = specific taxa). |
| **Correlation analysis** | Correlating microbiome composition (high‑dimensional) with immune read‑outs risks spurious associations. | Use dimension‑reduction (e.g., PCoA axes, PC1/PC2) or canonical correlation analysis; adjust for multiple comparisons; consider partial correlations controlling for diet group. |
| **Missing data handling** | If a mouse dies before day 21, you lose its immune data but may still have earlier clinical scores. | Mixed models can accommodate unbalanced data; otherwise, perform sensitivity analyses (e.g., worst‑case imputation). |

---

## 6. Practical Issues (what could go wrong)

| Potential problem | Impact | Mitigation |
|-------------------|--------|------------|
| **Diet palatability leading to reduced intake** | Weight loss, stress, confounded results. | Measure daily food intake per cage; if intake diverges >10 %, consider pair‑feeding or adding a non‑fermentable filler to match bulk. |
| **Fiber source variability** | Different fibers (inulin, cellulose, pectin) have distinct fermentation profiles → different SCFA profiles. | Choose a well‑characterized fiber (e.g., 5 % inulin) and document its composition; optionally measure fecal SCFAs to confirm fermentation. |
| **EAE induction failure** | Low disease incidence reduces power and may produce floor effects. | Standardise MOG‑35‑55 emulsion (sonication time, concentration), use adjuvant (pertussis toxin) at a fixed dose, and monitor for signs of inflammation; consider a pilot to confirm ~80 % incidence. |
| **Microbiome batch effects** | DNA extraction kit lot, PCR primers, sequencing run can introduce artefactual differences. | Randomise samples across extraction batches and sequencing lanes; include extraction blanks and a mock community; use the same primer set and sequencing depth for all samples. |
| **Flow cytometry variability** | Antibody staining, instrument settings, gating strategy can shift results. | Use a standardized staining panel, run fluorescence‑minus‑one (FMO) controls, and acquire a fixed number of events; consider using an automated gating algorithm (e.g., FlowJo + platform or Cytobank). |
| **Mouse mortality unrelated to treatment** | Attrition reduces n and may bias survivors (e.g., only resilient mice remain). | Record cause of death; if mortality >10 % in any group, consider humane endpoints early and analyse with survival models. |
| **Environmental fluctuations (temperature, humidity)** | Can affect gut permeability and immunity. | Keep housing conditions constant; log cage‑level temperature/humidity if possible. |
| **Blinding breach** | If the person scoring knows the diet, bias can creep in. | Use coded diet containers; have a separate person prepare diets and another perform scoring; keep codes until analysis is complete. |

---

## 7. Recommendations – Prioritized List  

### **Essential Fixes** (must do before starting)

1. **Add a pair‑fed or iso‑caloric control** for the high‑fiber diet to rule out caloric/bulk effects.  
2. **Collect baseline (day 0) microbiome and, if feasible, immune phenotypes** to confirm group equivalence and to use as covariates.  
3. **Model cage and litter as random effects** in all statistical analyses (mixed‑effects models for clinical scores; mixed‑effects PERMANOVA or stratified PERMANOVA for microbiome).  
4. **Perform an a priori power analysis** using pilot or published variance for the primary outcome (clinical EAE score) and adjust n accordingly (likely ≥14–16 per group).  
5. **Standardise the fiber source** (single, well‑characterized fiber) and, if possible, measure fecal short‑chain fatty acids (SCFAs) to confirm that the diet is indeed altering microbial fermentation.  

### **Highly Recommended** (strongly improves interpretability)

6. **Blind diet preparation and scoring** (double‑blind if feasible).  
7. **Include a sham‑diet control** to ensure any observed effect is not due to inadvertent changes in other nutrients when boosting fiber.  
8. **Add a mechanistic validation arm** (e.g., antibiotic depletion or germ‑free mice receiving faecal transplants) in a separate pilot to test microbiome dependence.  
9. **Collect longitudinal immune data** (e.g., blood or spleen at days 7 and 14) to see whether immune shifts precede clinical improvement.  
10. **Report and test for dispersion differences** (PERMDISP) alongside PERMANOVA for microbiome data.  

### **Nice‑to‑Have** (adds depth but not required for the core hypothesis)

11. **Sex‑balanced cohort** (add male mice) to assess generality across sexes.  
12. **Metabolomics (SCFA, bile acids) and/or host transcriptomics** (colon epithelium) to link microbiome changes to immune pathways.  
13. **Histopathology of spinal cord** (demyelination, inflammation) as an additional phenotypic read‑out.  
14. **Single‑cell RNA‑seq or CyTOF** on CNS infiltrates for high‑resolution immune profiling.  
15. **Long-term follow‑up** (recovery phase) to see whether fiber confers lasting protection.  

---

### Quick Checklist Before You Start  

- [ ] Diet sheets (macro‑ and micronutrient composition, fiber type, caloric density) finalized and matched across groups.  
- [ ] Food intake measurement plan (daily weighing of hoppers, spill correction).  
- [ ] Baseline sampling SOP (faecal + optional blood) at day 0.  
- [ ] Cage‑assignment SOP ensuring litter split across diets (if possible).  
- [ ] Randomisation list generated and kept blinded to diet preparation staff.  
- [ ] Power analysis document (effect size, α, power, resulting n).  
- [ ] Statistical analysis script (mixed‑effects model for scores, PERMANOVA + PERMDISP for 16S, FDR‑corrected taxa tests).  
- [ ] QC plan for microbiome (blanks, mock community, batch randomisation).  
- [ ] Blinding procedure for clinical scoring (code‑key kept separate until analysis).  

If you can confirm that items 1‑5 are addressed, the study will be in a strong position to test whether dietary fiber truly modulates the gut microbiome‑immune axis in EAE. Feel free to share any specifics (fiber type, diet formulation, pilot variance numbers) if you’d like me to weigh in on the power calculations or diet matching details. Good luck with the experiment!
````

## Assessment

_Machine-suggested (UNCONFIRMED) — drafted by Claude Opus 4.7 on 2026-06-26 to speed T4 review. An author must independently read the Model Output above and set the real Recommendation. Anything labeled here is triage, not domain expert review._

**Machine triage:** Output is complete with a final action-item checklist. Separates "essential fixes" from "nice-to-have improvements". Strong cross-model agreement on top concerns (cage, diet matching, sham controls).

**Suggested verdict (UNCONFIRMED):** Pass

**What still needs human verification:**
- Whether the essential-vs-nice-to-have separation is correctly drawn
- That the checklist items (mock community for QC, blinding code-key) are field-standard
- Spot-check the recommendation flow is internally consistent

## Overall Assessment
- **Recommendation:** Pass
- **Notes:** Alex Alexiev (2026-06-29): **What still needs human verification:**
- Whether the essential-vs-nice-to-have separation is correctly drawn: yes
- That the checklist items (mock community for QC, blinding code-key) are field-standard: yes
- Spot-check the recommendation flow is internally consistent: yes

## Verification Steps Tested
_Which verification requirements from the prompt were checked, and results._
